Literature DB >> 2057540

Stability and pharmacokinetics of flumazenil in the rat.

J W Mandema1, J M Gubbens-Stibbe, M Danhof.   

Abstract

The pharmacokinetics of flumazenil in the rat were determined after 2.5 mg/kg intravenous and 25 mg/kg oral administration. Following intravenous administration flumazenil was rapidly eliminated with an extremely short terminal half-life (mean +/- SE, n = 8) of 8.3 +/- 0.3 min due to a large total blood clearance of 147 +/- 7 ml/kg/min combined with a relatively small volume of distribution at steady-state of 1.33 +/- 0.07 l/kg. After oral administration flumazenil was rapidly absorbed; however, the bioavailability was low (28 +/- 4%) and variable. Flumazenil was found to be unstable in rat blood in vitro and disappeared with a half-life (mean +/- SE, n = 5) of 8.3 +/- 1 min and 31 +/- 4 min at body and room temperature, respectively. The blood samples were stabilized by addition of sodium fluoride (NaF) and cooling to 0 degrees C. The samples had to be stored at -35 degrees C when analyzed at later times. Presumably esterases in rat blood are responsible for the observed instability. A sensitive HPLC assay to measure flumazenil concentrations in small blood samples is also described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2057540     DOI: 10.1007/bf02244294

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

Review 1.  Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788.

Authors:  S E File; S Pellow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma.

Authors:  H Friedman; D R Abernethy; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Agonist and antagonist benzodiazepine receptor interaction in vitro.

Authors:  H Möhler; J G Richards
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions.

Authors:  L G Miller; D J Greenblatt; S M Paul; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

5.  Benzodiazepine antagonist Ro 15-1788: neurological and behavioral effects.

Authors:  E P Bonetti; L Pieri; R Cumin; R Schaffner; M Pieri; E R Gamzu; R K Müller; W Haefely
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Electrophysiological studies on the specific benzodiazepine antagonist Ro 15-1788.

Authors:  P Polc; J P Laurent; R Scherschlicht; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-07       Impact factor: 3.000

7.  In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution.

Authors:  R M Arendt; D J Greenblatt; R H deJong; J D Bonin; D R Abernethy; B L Ehrenberg; H G Giles; E M Sellers; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

Review 8.  Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

9.  Determination of the benzodiazepine antagonist Ro 15-1788 in plasma by high-performance liquid chromatography with UV detection.

Authors:  U Timm; M Zell
Journal:  Arzneimittelforschung       Date:  1983

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  8 in total

1.  Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.

Authors:  Lia C Liefaard; Bart A Ploeger; Carla F M Molthoff; Ronald Boellaard; Adriaan A Lammertsma; Meindert Danhof; Rob A Voskuyl
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

2.  GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals.

Authors:  M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

3.  Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.

Authors:  Philip W Moore; J Ward Donovan; Keith K Burkhart; Jeffrey A Waskin; Michelle A Hieger; Audrey R Adkins; Yijin Wert; David A Haggerty; J J Rasimas
Journal:  J Med Toxicol       Date:  2014-06

4.  Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.

Authors:  Severin Mairinger; Oliver Langer; Claudia Kuntner; Thomas Wanek; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Bernd Dörner; Florian Bauer; Christoph Baumgartner; Wolfgang Löscher; Thomas Erker; Markus Müller
Journal:  Nucl Med Biol       Date:  2010-04-08       Impact factor: 2.408

5.  Stress-induced changes in respiratory quotient, energy expenditure and locomotor activity in rats: effects of midazolam.

Authors:  I S McGregor; A M Lee; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

6.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors:  J W Mandema; M T Kuck; M Danhof
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

7.  In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.

Authors:  Stefanie Dedeurwaerdere; Marie-Claude Gregoire; Lucy Vivash; Peter Roselt; David Binns; Christopher Fookes; Ivan Greguric; Tien Pham; Christian Loc'h; Andrew Katsifis; Rodney J Hicks; Terence J O'Brien; Damian E Myers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-10       Impact factor: 9.236

8.  In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors:  Lucy Vivash; Marie-Claude Gregoire; Viviane Bouilleret; Alexis Berard; Catriona Wimberley; David Binns; Peter Roselt; Andrew Katsifis; Damian E Myers; Rodney J Hicks; Terence J O'Brien; Stefanie Dedeurwaerdere
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.